Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine

Anne L. Coleman, Alan L. Robin, Irvin P. Pollack, Michael T. Rudikoff, Cheryl Enger, Philip R. Mayer

Research output: Contribution to journalArticle

Abstract

We performed a double-masked, crossover study comparing the cardiovascular and intraocular pressure effects of 0.5% and 0.25% topical apraclonidine hydrochloride and 0.5% timolol maleate in 20 healthy female volunteers. The contralateral effects of unilateral apraclonidine and the plasma concentrations of apraclonidine were also assessed. All measurements were done 2, 5, and 8 hours after drop instillation. A 15-minute treadmill test was performed after the 2-hour measurements. All three active medications lowered intraocular pressure comparably. There was no significant contralateral intraocular pressure effect seen with apraclonidine. The apraclonidine plasma concentrations were variable and unrelated to the amount of intraocular pressure lowering and cardiovascular parameters measured. Apraclonidine did not affect blood pressure or heart rate any differently than placebo. Timolol, however, blunted exercise-induced tachycardia. There were no significant differences in pupillary diameters or interpalpebral fissure widths among treatment groups.

Original languageEnglish (US)
Pages (from-to)1264-1267
Number of pages4
JournalArchives of Ophthalmology
Volume108
Issue number9
DOIs
StatePublished - 1990

Fingerprint

Intraocular Pressure
Timolol
Exercise Test
Double-Blind Method
Tachycardia
Cross-Over Studies
apraclonidine
Healthy Volunteers
Heart Rate
Placebos
Exercise
Blood Pressure

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine. / Coleman, Anne L.; Robin, Alan L.; Pollack, Irvin P.; Rudikoff, Michael T.; Enger, Cheryl; Mayer, Philip R.

In: Archives of Ophthalmology, Vol. 108, No. 9, 1990, p. 1264-1267.

Research output: Contribution to journalArticle

Coleman, Anne L. ; Robin, Alan L. ; Pollack, Irvin P. ; Rudikoff, Michael T. ; Enger, Cheryl ; Mayer, Philip R. / Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine. In: Archives of Ophthalmology. 1990 ; Vol. 108, No. 9. pp. 1264-1267.
@article{792347ef80db4e90a7aae5aaf863e26b,
title = "Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine",
abstract = "We performed a double-masked, crossover study comparing the cardiovascular and intraocular pressure effects of 0.5{\%} and 0.25{\%} topical apraclonidine hydrochloride and 0.5{\%} timolol maleate in 20 healthy female volunteers. The contralateral effects of unilateral apraclonidine and the plasma concentrations of apraclonidine were also assessed. All measurements were done 2, 5, and 8 hours after drop instillation. A 15-minute treadmill test was performed after the 2-hour measurements. All three active medications lowered intraocular pressure comparably. There was no significant contralateral intraocular pressure effect seen with apraclonidine. The apraclonidine plasma concentrations were variable and unrelated to the amount of intraocular pressure lowering and cardiovascular parameters measured. Apraclonidine did not affect blood pressure or heart rate any differently than placebo. Timolol, however, blunted exercise-induced tachycardia. There were no significant differences in pupillary diameters or interpalpebral fissure widths among treatment groups.",
author = "Coleman, {Anne L.} and Robin, {Alan L.} and Pollack, {Irvin P.} and Rudikoff, {Michael T.} and Cheryl Enger and Mayer, {Philip R.}",
year = "1990",
doi = "10.1001/archopht.1990.01070110080029",
language = "English (US)",
volume = "108",
pages = "1264--1267",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine

AU - Coleman, Anne L.

AU - Robin, Alan L.

AU - Pollack, Irvin P.

AU - Rudikoff, Michael T.

AU - Enger, Cheryl

AU - Mayer, Philip R.

PY - 1990

Y1 - 1990

N2 - We performed a double-masked, crossover study comparing the cardiovascular and intraocular pressure effects of 0.5% and 0.25% topical apraclonidine hydrochloride and 0.5% timolol maleate in 20 healthy female volunteers. The contralateral effects of unilateral apraclonidine and the plasma concentrations of apraclonidine were also assessed. All measurements were done 2, 5, and 8 hours after drop instillation. A 15-minute treadmill test was performed after the 2-hour measurements. All three active medications lowered intraocular pressure comparably. There was no significant contralateral intraocular pressure effect seen with apraclonidine. The apraclonidine plasma concentrations were variable and unrelated to the amount of intraocular pressure lowering and cardiovascular parameters measured. Apraclonidine did not affect blood pressure or heart rate any differently than placebo. Timolol, however, blunted exercise-induced tachycardia. There were no significant differences in pupillary diameters or interpalpebral fissure widths among treatment groups.

AB - We performed a double-masked, crossover study comparing the cardiovascular and intraocular pressure effects of 0.5% and 0.25% topical apraclonidine hydrochloride and 0.5% timolol maleate in 20 healthy female volunteers. The contralateral effects of unilateral apraclonidine and the plasma concentrations of apraclonidine were also assessed. All measurements were done 2, 5, and 8 hours after drop instillation. A 15-minute treadmill test was performed after the 2-hour measurements. All three active medications lowered intraocular pressure comparably. There was no significant contralateral intraocular pressure effect seen with apraclonidine. The apraclonidine plasma concentrations were variable and unrelated to the amount of intraocular pressure lowering and cardiovascular parameters measured. Apraclonidine did not affect blood pressure or heart rate any differently than placebo. Timolol, however, blunted exercise-induced tachycardia. There were no significant differences in pupillary diameters or interpalpebral fissure widths among treatment groups.

UR - http://www.scopus.com/inward/record.url?scp=0025070973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025070973&partnerID=8YFLogxK

U2 - 10.1001/archopht.1990.01070110080029

DO - 10.1001/archopht.1990.01070110080029

M3 - Article

C2 - 2205182

AN - SCOPUS:0025070973

VL - 108

SP - 1264

EP - 1267

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -